EZH2 and ovarian carcinoma: In addition to studies that focus on the events downstream of EZH2, several studies describe the roles of microRNAs and lncRNAs in a cascade that leads to changed EZH2 expression or activity and a subsequent modulation of cisplatin resistance in ovarian cancer.